Brief: CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial
30/05/2025 13:52
May 30 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS HOLDINGS, INC. DOSES FIRST PATIENT WITH CER-1236 IN PHASE 1 CLINICAL TRIAL FOR ACUTE MYELOID LEUKEMIA AND IS ADVANCING THROUGH PROTOCOL-DEFINED EVALUATIONS Source text: ID:nGNX6q1QKk Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List